Walter, Roland BPotter, VictoriaCraddock, Charles2024-10-032024-10-032024-09-06Walter RB, Potter V, Craddock C. Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in Adults over 70 years old. Blood. 2024 Sep 6:blood.2024024247. doi: 10.1182/blood.2024024247. Epub ahead of print0006-49711528-002010.1182/blood.202402424739241195http://hdl.handle.net/20.500.14200/6012The advent of reduced-intensity conditioning regimens, improvements in graft-versus-host disease prophylaxis, and better supportive care have permitted increasing use of allogeneic hematopoietic cell transplantation (allo-HCT) in adults age ≥70 with AML. However, while potentially curative, non-relapse mortality and relapse represent the main causes of treatment failure, highlighting the importance of refining both patient selection and transplant strategies. At the same time, continuously evolving non-transplant therapies and transplant technologies mandate prospective trials (re-)examining the role of allo-HCT and its optimal delivery.enCopyright © 2024 American Society of Hematology.HaematologyArticle